Viral Vectors for Cancer Therapy
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Trevor Parry, Dana Michelle Previte, Mary Jane Duermeyer
Life of this patent
Estimating the term…
Abstract
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.
Claims35
-83. (canceled)
A method of expressing, enhancing, increasing, augmenting, or supplementing the levels of an Interleukin (IL)-12 polypeptide and an IL-2 polypeptide in one or more cells of a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising:
- (a) a herpes simplex virus comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises a polynucleotide encoding the Interleukin (IL)-12 polypeptide and a polynucleotide encoding the IL-2 polypeptide;
- and
- (b) a pharmaceutically acceptable excipient,
- wherein the IL-12 polypeptide comprises an IL-12 subunit alpha polypeptide and an IL-12 subunit beta polypeptide connected by a linker polypeptide, and
- wherein the recombinant herpes simplex virus genome further comprises a first promoter operably linked to the polynucleotide encoding the IL-12 polypeptide and a second promoter operably linked to the polynucleotide encoding IL-2 polypeptide.
A method of expressing, enhancing, increasing, augmenting, or supplementing the levels of an IL-12 polypeptide and an IL-2 polypeptide in one or more cells of a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising:
- (a) a population of herpes simplex viruses, wherein the population of herpes simplex viruses comprises recombinant herpes simplex virus genomes comprising a polynucleotide encoding the IL-12 polypeptide and a polynucleotide encoding the IL-2 polypeptide;
- and
- (b) a pharmaceutically acceptable excipient,
- wherein the IL-12 polypeptide comprises an IL-12 subunit alpha polypeptide and an IL-12 subunit beta polypeptide connected by a linker polypeptide, and
- wherein the recombinant herpes simplex virus genomes further comprise a first promoter operably linked to the polynucleotide encoding the IL-12 polypeptide and a second promoter operably linked to the polynucleotide encoding the IL-2 polypeptide.
Dependencies are inferred from the claim text.